Indian Immunologicals rolls out India’s first indigenously developed Hepatitis A vaccine Havisure

The first dose is administered at above 12 months of age and the second dose is given at least after six months of the first dose Indian Immunologicals Ltd (IIL), a wholly-owned subsidiary of National Dairy Development Board (NDDB) and a leading biopharmaceutical company in India, has launched India’s first indigenously developed Hepatitis A vaccine Havisure. Dr K Anand Kumar, MD, Indian Immunologicals Ltd shared, "The launch of Havisure is a testament to our commitment to advancing healthcare solutions for the nation. Currently, Hepatitis A vaccines are imported into our country and as a true meaning of Atma Nirbhar Bharat, IIL has tirelessly put in efforts and developed India’s 1st vaccine for Hepatitis A. The vaccine Havisure has undergone extensive clinical trials in eight centres and has proven to be safe and efficacious. The vaccine is comparable to the world’s leading vaccine sold by a multinational. With Havisure®, we aim to contribute significantly to the prevention of this infectious disease. IIL launching three vaccines in a single year is itself a big achievement and full credit to my team.” Havisure is set to play a crucial role in protecting against the Hepatitis A virus, which primarily affects the liver. The vaccine is effective in preventing the disease and is recommended for children in routine immunisation. It is a two-dose vaccine wherein the first dose is administered at above 12 months of age and the second dose is given at least after six months of the first dose. The vaccine is also recommended for individuals who are at risk of exposure or travel to regions with high hepatitis A prevalence. In addition to this people with occupational risk of infection and suffering from chronic liver diseases also need Hepatitis A vaccination. Dr Priyabrata Pattnaik, Dy Managing Director, IIL said, “The company has considerably invested in state-of-the-art manufacturing facilities to scale up production and meet the growing demand for Hepatitis A vaccine. As part of the launch, IIL will be collaborating with healthcare professionals, corporate hospitals, and government agencies to promote awareness about Hepatitis A and the importance of both paediatric, adolescent and adult vaccination.”